Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06560632

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06560632. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR Trial)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, open-label Phase 1 trial to investigate the safety, PK, and pharmacodynamics of the Polθ inhibitor RP-3467 alone or in combination with the poly-ADP ribose polymerase inhibitor (PARPi) olaparib in adults with molecularly selected advanced solid tumors.

Study identification

NCT ID: NCT06560632
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Repare Therapeutics; Industry
Enrollment: 26 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 17, 2024 (Actual)
Primary completion: Oct 28, 2025 (Actual)
Completion: Oct 28, 2025 (Actual)
Last update posted: Jan 16, 2026

2024 – 2025

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
# 1025, The University of California	San Francisco	California	94158	—
# 1011, The Washington University	St Louis	Missouri	63130	—
# 1008, Columbia University	New York	New York	10032	—
# 1004, Memorial Sloan-Kettering Cancer Center	New York	New York	10065	—
# 1001, The University of Texas M.D. Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06560632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 16, 2026 · Synced Nov 14, 2026